Show items per page
Elements: 6
Page 1 on 1
 TitleAuthors / EditorsDate
add to browser selection
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Finckh, Axel; Ciurea, A.; Brulhart, L.; Moller, B.; ... Gabay, Cem 2010
add to browser selection
Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death Golay, Josee; Bologna, Luca; Andre, Pierre-Alain; Buchegger, Franz; ... Introna, Martino 2010
add to browser selection
Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants Wilbur, D Scott; Park, Steven I.; Chyan, Ming-Kuan; Wan, Feng; ... Press, Oliver W. 2010
add to browser selection
Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles Cirstoiu, Adriana; Bossy-Nobs, L.; Buchegger, Franz; Gurny, Robert; Delie Salmon, Florence 2007
add to browser selection
Biodegradable nanoparticles for direct or two-step tumor immunotargeting Nobs, Leila; Buchegger, Franz; Gurny, Robert; Allémann, Eric 2006
add to browser selection
Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody Alwayn, I P; Xu, Y; Basker, M; Wu, C; ... Cooper, D K 2001